HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshihiko Hirohashi Selected Research

HSP40 Heat-Shock Proteins

10/2016A novel nuclear DnaJ protein, DNAJC8, can suppress the formation of spinocerebellar ataxia 3 polyglutamine aggregation in a J-domain independent manner.
1/2016Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshihiko Hirohashi Research Topics

Disease

130Neoplasms (Cancer)
06/2022 - 05/2002
17Carcinoma (Carcinomatosis)
11/2022 - 05/2006
13Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 06/2004
11Lung Neoplasms (Lung Cancer)
01/2019 - 02/2005
10Renal Cell Carcinoma (Grawitz Tumor)
04/2022 - 07/2007
10Neoplasm Metastasis (Metastasis)
03/2020 - 01/2013
10Breast Neoplasms (Breast Cancer)
04/2017 - 02/2005
10Colonic Neoplasms (Colon Cancer)
01/2017 - 10/2005
8Sarcoma (Soft Tissue Sarcoma)
02/2021 - 01/2016
7Testicular Neoplasms (Testicular Cancer)
01/2020 - 06/2012
6Prostatic Neoplasms (Prostate Cancer)
01/2022 - 12/2009
6Osteosarcoma (Osteogenic Sarcoma)
10/2020 - 01/2003
6Adenocarcinoma
08/2020 - 02/2005
6Hypoxia (Hypoxemia)
08/2020 - 11/2009
5Uterine Cervical Neoplasms (Cancer of the Cervix)
09/2021 - 02/2012
5Carcinogenesis
01/2021 - 02/2012
4Urinary Bladder Neoplasms (Bladder Cancer)
04/2022 - 05/2006
4Pancreatic Neoplasms (Pancreatic Cancer)
08/2019 - 05/2003
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2011 - 08/2002
4Melanoma (Melanoma, Malignant)
02/2010 - 02/2005
3Tuberculosis (Tuberculoses)
03/2021 - 10/2007
3Squamous Cell Carcinoma of Head and Neck
11/2018 - 08/2002
3Ovarian Neoplasms (Ovarian Cancer)
05/2016 - 01/2013
3Tics (Tic)
08/2013 - 03/2010
3Mouth Neoplasms (Oral Cancer)
02/2011 - 01/2009
2Microsatellite Instability
01/2022 - 01/2017
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2021 - 01/2017
2Inflammation (Inflammations)
01/2021 - 01/2016
2Adenocarcinoma of Lung
11/2020 - 01/2013
2Kidney Neoplasms (Kidney Cancer)
03/2018 - 12/2017
2Neuroblastoma
10/2016 - 01/2004
2Ovarian Epithelial Carcinoma
12/2014 - 01/2013
2Synovial Sarcoma (Synovioma)
12/2002 - 08/2002
1Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
06/2022

Drug/Important Bio-Agent (IBA)

51AntigensIBA
04/2022 - 05/2002
50Peptides (Polypeptides)IBA
04/2022 - 05/2002
30Proteins (Proteins, Gene)FDA Link
05/2022 - 06/2002
19SurvivinIBA
02/2020 - 06/2002
16Immune Checkpoint InhibitorsIBA
11/2022 - 01/2016
12HLA Antigens (Human Leukocyte Antigens)IBA
10/2020 - 08/2006
11HLA-A24 AntigenIBA
10/2020 - 07/2002
10Protein Subunit VaccinesIBA
08/2019 - 06/2004
9EpitopesIBA
01/2018 - 06/2002
9Cancer VaccinesIBA
01/2014 - 05/2002
7Aldehyde Dehydrogenase 1 FamilyIBA
01/2022 - 10/2012
6Messenger RNA (mRNA)IBA
01/2020 - 08/2009
6Inhibitor of Apoptosis ProteinsIBA
02/2011 - 02/2005
4Biomarkers (Surrogate Marker)IBA
01/2022 - 06/2009
4Aldehyde DehydrogenaseIBA
01/2022 - 07/2012
4NivolumabIBA
07/2021 - 01/2019
4Monoclonal AntibodiesIBA
04/2018 - 06/2009
4Heat-Shock Proteins (Heat-Shock Protein)IBA
03/2018 - 04/2011
4Oxidoreductases (Dehydrogenase)IBA
04/2017 - 05/2015
4Histocompatibility Antigens Class IIBA
01/2017 - 01/2015
4Small Interfering RNA (siRNA)IBA
04/2016 - 10/2005
4VaccinesIBA
02/2016 - 04/2009
4Neoplasm Antigens (Tumor Antigens)IBA
01/2014 - 05/2003
4Complementary DNA (cDNA)IBA
01/2013 - 08/2004
4AutoantibodiesIBA
05/2011 - 05/2005
3LigandsIBA
11/2021 - 01/2014
3B7-H1 AntigenIBA
11/2020 - 04/2017
3incomplete Freund's adjuvantIBA
02/2020 - 06/2011
3Phosphotransferases (Kinase)IBA
10/2017 - 12/2005
3Coloring Agents (Dyes)IBA
10/2013 - 04/2011
3HLA-A Antigens (HLA-A)IBA
02/2005 - 05/2002
2Therapeutic UsesIBA
05/2022 - 08/2006
2pembrolizumabIBA
07/2021 - 11/2020
2Photosensitizing Agents (Photosensitizers)IBA
02/2021 - 01/2019
21-phenyl-3,3-dimethyltriazene (PDT)IBA
02/2021 - 01/2019
2Epidermal Growth Factor (EGF)IBA
01/2021 - 10/2017
2EnzymesIBA
08/2020 - 05/2015
2Interferon-alpha (Interferon Alfa)IBA
02/2020 - 01/2013
2GemcitabineFDA Link
08/2019 - 10/2018
2Interleukin-6 (Interleukin 6)IBA
01/2019 - 01/2016
2AcidsIBA
01/2019 - 05/2002
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2019 - 01/2016
2Immune Checkpoint ProteinsIBA
04/2017 - 01/2016
2HSP40 Heat-Shock ProteinsIBA
10/2016 - 01/2016
2Transcription Factors (Transcription Factor)IBA
08/2016 - 08/2011
2AldehydesIBA
06/2016 - 01/2013
2Oxygen (Dioxygen)IBA
04/2016 - 11/2009
2Biological ProductsIBA
02/2016 - 04/2009
2CytokinesIBA
01/2016 - 05/2003
2RecoverinIBA
01/2015 - 07/2002
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2015 - 04/2013
2DNA (Deoxyribonucleic Acid)IBA
04/2013 - 02/2012
2InterferonsIBA
01/2013 - 06/2009
2bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
12/2011 - 04/2011
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
01/2009 - 06/2002
2AntibodiesIBA
05/2006 - 05/2005
1Antineoplastic Agents (Antineoplastics)IBA
11/2022
1Cytotoxins (Cytolysins)IBA
11/2022
1Vincristine (Oncovin)FDA LinkGeneric
06/2022

Therapy/Procedure

50Immunotherapy
06/2022 - 05/2002
41Therapeutics
11/2022 - 06/2004
20Drug Therapy (Chemotherapy)
11/2022 - 08/2004
15Radiotherapy
05/2022 - 03/2010
4Chemoradiotherapy
05/2022 - 08/2013
3Aftercare (After-Treatment)
03/2021 - 01/2013
2Nephrectomy
03/2020 - 05/2011